Federal Circuit holds that isolated DNA molecules are patent-eligible subject matter

Today the U.S. Court of Appeals for the Federal Circuit issued its much-anticipated opinion in Association for Molecular Pathology (AMP) and ACLU v. USPTO and Myriad Genetics (Fed. Cir. 2012).  In the decision, the Court held that claims directed to isolated DNA molecules and methods of screening potential anti-cancer therapeutics are patent-eligible subject matter.

My colleagues Gerard Norton and Jianming Jimmy Hao have published a more detailed summary of the Federal Circuit’s decision, available via this link.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s